Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

403P Gender trend over time of principal investigators within large Australian cancer clinical trials groups

Autor: T.T.V. Luong, C.H. Ho, V. Aedo-Lopez, E. Segelov

Publikováno v: Annals of Oncology. 33:S1600

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad86d4f25307871414491ce6ea8702e7
https://doi.org/10.1016/j.annonc.2022.10.434

Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study

Autor: Lopes, A. M. D. S., Colomer-Lahiguera, S., Mederos-Alfonso, N-N., Lopez, V. Aedo, Spurrier-Bernard, G., Tolstrup, L. K., Pappot, H., Aspeslagh, S., Rogiers, A., Neyns, B., Haanen, J. B. A. G., Mitchell, S. A., Addeo, A., Michielin, O. A., Eicher, M.

Publikováno v: Lopes, A M D S, Colomer-Lahiguera, S, Mederos-Alfonso, N-N, Lopez, V A, Spurrier-Bernard, G, Tolstrup, L K, Pappot, H, Aspeslagh, S, Rogiers, A, Neyns, B, Haanen, J B A G, Mitchell, S A, Addeo, A, Michielin, O A & Eicher, M 2021, ' Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study ', Annals of Oncology, vol. 32, no. Suppl. 5, 1686P, pp. S1180 . https://doi.org/10.1016/j.annonc.2021.08.1658

Background: Immune-related Adverse Events (IrAEs) present a new challenge to patient safety. The use of Patient-Reported Outcomes (PROs) to monitor adverse events is increasing. Existing measures like the PRO version of the Common Terminology Criteri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a2408daf0ee6f14687c93c1fc0ed3542
https://biblio.vub.ac.be/vubir/selecting-patientreported-outcomes-to-monitor-symptomatic-toxicities-of-immunecheckpoint-inhibitors-a-delphi-study(b99b8fb7-4dce-4f0f-b368-3597a72fa2c3).html

1686P Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study

Autor: J.B.A.G. Haanen, G. Spurrier-Bernard, Alfredo Addeo, Anne Rogiers, S. Colomer-Lahiguera, Lærke Kjær Tolstrup, Olivier Michielin, V Aedo Lopez, Bart Neyns, Helle Pappot, Sandra A. Mitchell, Sandrine Aspeslagh, N-N. Mederos-Alfonso, A.M.D.S. Lopes, Manuela Eicher

Publikováno v: Annals of Oncology. 32:S1180

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a18e78dba82463475d9fb67828c5ec16
https://doi.org/10.1016/j.annonc.2021.08.1658

Real life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland

Autor: F. Weihsengruber, M. Karasek, J. Kofler, Peter Koelblinger, Christoph Hoeller, Erika Richtig, Christine Hafner, J.M. Ressler, Olivier Michielin, V Aedo Lopez, H. Kehrer, Lukas Koch

Publikováno v: Annals of Oncology. 30:v548-v549

Background Talimogene Laherparepvec (TVEC), a genetically modified GM-CSF expressing HSV1 Virus that preferentially replicates in tumor cells is approved in Europe for use in melanoma patients with injectable metastatic lesions in stage III-IVM1a. Ap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1c1f501f588bf39377c75465ea00dbf
https://doi.org/10.1093/annonc/mdz255.032